Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.72 |
| ▸ | TGM2 | P21980 | 1/20 | 0.71 |
| ▸ | KRAS | P01116 | 5/20 | 0.65 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.64 |
| ▸ | IMPDH2 | P12268 | 6/20 | 0.61 |
| ▸ | IMPDH1 | P20839 | 2/20 | 0.61 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.61 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.61 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.61 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.60 |
| ▸ | P2RY1 | P47900 | 2/20 | 0.60 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.60 |
| ▸ | HINT1 | P49773 | 1/20 | 0.60 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.59 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.59 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.59 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.59 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.59 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4410906 | 0.97 | NT5E (0.74) | NT5ETGM2KRASFUT5IMPDH2 | |
| SCHEMBL28275952 | 0.96 | NT5E (0.75) | NT5ETGM2KRASFUT5IMPDH2 | |
| SCHEMBL8501729 | 0.95 | NT5E (0.74) | NT5ETGM2KRASFUT5IMPDH2 | |
| SCHEMBL28222628 | 0.95 | NT5E (0.74) | NT5ETGM2KRASFUT5IMPDH2 | |
| SCHEMBL27819299 | 0.95 | NT5E (0.74) | NT5ETGM2KRASFUT5IMPDH2 | |
| SCHEMBL574773 | 0.95 | NT5E (0.74) | NT5ETGM2KRASFUT5IMPDH2 | |
| SCHEMBL4366555 | 0.94 | NT5E (0.73) | NT5ETGM2KRASFUT5IMPDH2 | |
| SCHEMBL28597191 | 0.94 | NT5E (0.73) | NT5ETGM2KRASFUT5IMPDH2 | |
| SCHEMBL15747222 | 0.93 | NT5E (0.71) | NT5ETGM2KRASFUT5IMPDH2 | |
| SCHEMBL20850061 | 0.93 | NT5E (0.71) | NT5ETGM2KRASFUT5IMPDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060135467-A1 | Partial and full agonists of A1 adenosine receptors | ZABLOCKI JEFF | 2006-06-22 | — | — | US | disclosed |
| US-7022681-B2 | Partial and full agonists of A1 adenosine receptors | CV THERAPEUTICS, INC. (US) | 2006-04-04 | — | — | US | disclosed |
| EP-1537133-A2 | PARTIAL AND FULL AGONISTS OF A1 ADENOSINE RECEPTORS | CV THERAPEUTICS, INC. (US) | 2005-06-08 | — | — | EP | disclosed |
| US-20040043960-A1 | Partial and full agonists of A1 adenosine receptors | CV THERAPEUTICS, INC. | 2004-03-04 | — | — | US | disclosed |
| WO-2004016635-A2 | PARTIAL AND FULL AGONISTS OF A1 ADENOSINE RECEPTORS | CV THERAPEUTICS, INC. (US) | 2004-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135467-A1 | Partial and full agonists of A1 adenosine receptors | ADORA1, ADORA2A, ADORA3 | NT5E 638/4885TGM2 3887/4885KRAS 4339/4885 |
| US-20040043960-A1 | Partial and full agonists of A1 adenosine receptors | ADORA1, ADORA2A, ADORA3 | NT5E 710/4885TGM2 3851/4885KRAS 4291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.